
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is a company with a strong pipeline focused on developing cutting-edge, one-time gene therapies for neurodegenerative diseases. However, the company faces financing risks due to the challenging environment in the biotechnology and gene therapy industries, which may hinder its ability to continue development of its pipeline. If regulatory data for their lead candidate PBFT02 is positive, the company may struggle to secure sufficient capital to progress the program into a pivotal trial in the near future.
Bears say
Passage Bio is facing significant challenges in obtaining regulatory approval for their lead program, PBFT02, due to the FDA's insistence on a randomized controlled registrational study. The company's projected cash per share at YE26 may not be enough to cover the costs of this study and sustain operations until then. With uncertainties surrounding their key asset and a lack of flexibility from the FDA, investors should exercise caution when considering this stock.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares